Record overview
Status and phase
Status: COMPLETED
Phase: PHASE1, PHASE2
Sponsor: Bristol-Myers Squibb
Condition: CANCER,NOS
NCT01714739
A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: stale_update_signal
Results signal: Low Signal
Operational burden: large_enrollment_target_signal | strict_eligibility_signal
Stopped reason
Context when available
No stop reason available in the current public record.